All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

November 2, 2008

Pharmaceutical Technology

Pharmaceutical Technology-11-02-2008
Volume32
Issue 11

Trends In: FDA Enforcement Actions

Author(s):

Angie Drakulich

During the past five-plus years, the number of US Food and Drug Administration enforcement actions seems to have dropped significantly in the areas of seizures, permanent injunctions, and warning letters (see table). One may question whether the drop means companies are in better compliance these days, or whether FDA's drained resources are preventing the agency from following up every potential violation. Alyson Saben in the Office of Enforcement at FDA's Office of Regulatory Affairs provided some insight into this issue.

FDA Enforcement, FY 2003–FY 2008.

"In many cases, agency enforcement actions are taken for matters that are of greatest public health concern and which will have the greatest impact on consumer protection," she said. "We cannot measure the agency's enforcement success—nor can we measure industry compliance—by counting warning letters and other actions, individually."

These actions represent only a small portion of the "full spectrum of FDA's compliance efforts and the overall impact of those actions on consumer protection," adds Saben. For example, the statistics in the table do not include the accomplishments of FDA's Office of Criminal Investigations (OCI). In fiscal year 2008 (FY 2008), as of Sept. 10, OCI initiated 405 criminal investigations, made 319 arrests, and secured 311 convictions with fines, restitutions, and other monetary penalties totaling more than $153 million.

In addition, FDA's efforts in the import arena have a large impact in the enforcement arena. In 2007, the agency processed approximately 16 million lines of FDA-regulated products contained in import entries. Through the use of administrative actions such as Import Alerts and sampling efforts at the border, numerous, potentially violative, FDA-regulated products of foreign origin were prevented from reaching US consumers. And numerous other FDA "interventions," including inspections, sample collections/analyses, and issuance of 483s, take place daily, explained Saben, which result in corrective actions and consumer protection.

"The agency also seeks to expand the impact of these actions through its communication efforts, thereby achieving a broader, potential deterrent effect industry-wide," says Saben.

Articles in this issue

The Ideal Pharmacopeia
i2-564664-1408652835781.gif
The Role of Dendrimers in Topical Drug Delivery
i2-564659-1408652858920.gif
Nanotechnology Challenges FDA and Manufacturers
i1-564661-1408652852847.jpg
Exploring Solid-State Chemistry
i1-564652-1408652882509.jpg
Bringing Certainties to a Burgeoning Field
i1-564669-1408652812017.jpg
Pharma Capsules

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.
Related Content
Advertisement
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 29th 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 29th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 29th 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 29th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey
August 29th 2025

Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey

Christopher Cole
A hand is placing the final wooden block with a green certificate checkmark, symbolizing achievement, quality assurance and completion, against a plain pastel blue background. | Image credit: TimmyTimTim – stock.adobe.com
August 29th 2025

Continued Process Verification Is Critical in Pharmaceutical Manufacturing

Philip Hoersch
Related Content
Advertisement
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 29th 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 29th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 29th 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 29th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey
August 29th 2025

Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey

Christopher Cole
A hand is placing the final wooden block with a green certificate checkmark, symbolizing achievement, quality assurance and completion, against a plain pastel blue background. | Image credit: TimmyTimTim – stock.adobe.com
August 29th 2025

Continued Process Verification Is Critical in Pharmaceutical Manufacturing

Philip Hoersch
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.